论文部分内容阅读
目的探讨多肿瘤标志物蛋白芯片技术在人群防癌普查中的应用价值。方法采用多肿瘤标志物蛋白芯片技术对4624例接受健康体检的人员进行癌胚抗原(CEA)、甲胎蛋白(AFP)、糖链抗原242(CA242)、CA199、CA125、CA153、神经元特异性烯醇化酶(NSE)、铁蛋白、β人绒毛膜促性腺激素(β-hCG)、游离前列腺特异性抗原(fPSA)、PSA、人生长激素(hGH)12种肿瘤相关抗原物检测。结果 4624例体检人员中筛查出133例血清肿瘤标志物水平升高,其中18例经内窥镜、病理学、影像学检查确诊为早期或中期肿瘤,肿瘤检出率为0.39%。男、女受检者血清CEA、铁蛋白、β-hCG、fPSA、PSA、CA125的差异,<55岁年龄组、≥55岁年龄组受检者血清β-hCG、fPSA、PSA的差异以及肿瘤与非肿瘤受检者血清CA199、NSE、CA242、CEA、AFP、CA125的差异有统计学意义(P<0.05)。结论多肿瘤标志物蛋白芯片检测技术适用于人群的防癌普查。
Objective To explore the value of multi-tumor marker protein chip technology in the crowd anti-cancer screening. Methods A total of 4624 healthy subjects were tested for CEA, AFP, CA242, CA199, CA125, CA153 and neuronal specificity by using multiple tumor marker protein chip technology. Enolase (NSE), ferritin, β-hCG, fPSA, PSA and hGH. Results Among the 4624 medical staff, 133 cases of serum tumor markers were screened. Among them, 18 cases were diagnosed as early stage or medium stage by endoscopy, pathology and imaging examination. The detection rate of tumor was 0.39%. Differences of Serum CEA, Ferritin, β-hCG, fPSA, PSA and CA125 in Male and Female Subjects, Serum β-hCG, fPSA and PSA in 55 Years Old and 55 Years Old Patients There was a significant difference between the serum CA199, NSE, CA242, CEA, AFP and CA125 in non-tumor subjects (P <0.05). Conclusion Multi-tumor marker protein chip detection technology is suitable for the crowd of anti-cancer screening.